Disproportionality Analysis of Hematologic Adverse Event Signals Associated with Venetoclax in Combination with Senescence-Inducing Chemotherapy.

Saleh T, Ramadan M, Alsoud A, Al Shboul S

Open source

DOI
10.3390/jcm15062194
Published
2026 Mar 13
Container
Journal of clinical medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/jcm15062194,
  title = {Disproportionality Analysis of Hematologic Adverse Event Signals Associated with Venetoclax in Combination with Senescence-Inducing Chemotherapy.},
  author = {Saleh T and Ramadan M and Alsoud A and Al Shboul S},
  year = {2026},
  journal = {Journal of clinical medicine},
  doi = {10.3390/jcm15062194},
  url = {https://doi.org/10.3390/jcm15062194}
}

RIS

TY  - JOUR
TI  - Disproportionality Analysis of Hematologic Adverse Event Signals Associated with Venetoclax in Combination with Senescence-Inducing Chemotherapy.
AU  - Saleh T
AU  - Ramadan M
AU  - Alsoud A
AU  - Al Shboul S
PY  - 2026
JO  - Journal of clinical medicine
DO  - 10.3390/jcm15062194
UR  - https://doi.org/10.3390/jcm15062194
ER  - 

APA

T, S., M, R., A, A., & S, A. S. (2026). Disproportionality Analysis of Hematologic Adverse Event Signals Associated with Venetoclax in Combination with Senescence-Inducing Chemotherapy.. Journal of clinical medicine. https://doi.org/10.3390/jcm15062194

Source records